摘要
Abstract
Objective To explore the recent curative effect of Paclitaxel, Pharmorubicin weekly neoadjuvant chemotherapy in the treatment of locally advanced breast cancer.Methods 49 patients with locally advanced breast cancer treated in our hospital from 2012 to 2014 were randomly divided into two groups. 24 patients of observation group were given paclitaxel 70mg/m2, pharmorubicin 30mg/m2, 1 time/week, continue 3 weeks, 4 weeks as a cycle; 25 patients of Control group were given Paclitaxel 135 mg/m2, Pharmorubicin 80mg/m2, d1, 3 weeks as a cycle; patients of two groups were treated for three cycles, recent curative effect and side effects of two groups were compared.Results Total effective rate was 87.50% in observation group, and 72.00% in control group, the difference between two groups was statistically significant (P<0.05). After neoadjuvant chemotherapy, Postoperative pathological results showed pathologic complete response rate of observation group was obviously higher than that of control group, the difference was statistically significant (P<0.05).The adverse reaction such as nausea, vomiting, hair loss, neutropenia, thrombocytopenia, and muscle joint pain compared, there were no statistically significant difference (P>0.05). Conclusion Paclitaxel, pharmorubicin weekly neoadjuvant chemotherapy in treatment of locally advanced breast cancer increases the dose density, with higher total efficacy and no obvious recent adverse reaction, worthy of further research and application.关键词
紫杉醇/阿霉素/局部晚期乳腺癌/临床疗效/毒副反应Key words
Paclitaxel/Pharmorubicin/Locally advanced breast cancer/Clinical curative effect/Adverse reaction分类
医药卫生
